Could the next ovarian cancer breakthrough be traced back to a Commodore 64 home computer? After all, in some small measure, OCRA grantee Dr. Sohrab Shah is where he is today thanks to that now-antiquated instrument. He was 11 or 12 years old, tinkering around with programming at home, when he became captivated with what … Continued
An international collaborative of scientists, including Dr. Ronald Chandler at Michigan State University, studied ARID1A mutations, which are specific gene mutations observed in deep ovarian and deep infiltrating endometriosis. The authors of the study noted that seeing a high frequency of these mutations in deep ovarian endometriosis supports evidence linking this to endometriosis-associated ovarian cancer. … Continued
We’re full on into fall, and giving thanks for all that we’ve accomplished together, in a year that’s been more than a little challenging. RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
A bright spot in 2020 for the ovarian cancer community has been the ongoing developments in research and treatments. Advances continue to be made, as researchers study the effectiveness of PARP inhibitors as maintenance therapy for ovarian cancer, the most effective way to implement immunotherapy agents, the key factors that can affect the success of … Continued
Want to learn what’s new in ovarian cancer research and care for 2020? Start here. This fall, we hosted our virtual Uniting for Hope Ovarian Cancer National Conference, where experts in the field presented on a wide range of topics– demystifying genetic testing and precision medicine, providing resources for financial support, explaining clinical trials, and … Continued
There is an 80% recurrence rate when it comes to ovarian cancer, so the question of ‘what next?’ takes on a huge importance. This is the question that Sarah Gitto, PhD, and her team in the Daniel J. Powell Lab at the University of Pennsylvania’s Ovarian Cancer Research Center, have set out to answer. They … Continued
In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation. Watch the full FDA listening session in the video below.
It’s been an incredibly busy end of summer/beginning of fall here at OCRA with a double header of Ovarian Cancer Awareness Month and our Uniting for Hope Ovarian Cancer National Conference. We’ve learned so much and strengthened our community. Here are just some of the ways: RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS OCRA HEROES EVENTS WAYS TO … Continued
In order to understand the complexities of how gene mutations affect an ovarian cancer diagnosis, OCRA-funded researcher Alexander Nikitin, MD, PhD and colleagues looked to see which ones drive, or possibly delay, the onset of the disease. “We found there were various genes that would help the process along, but interestingly, there were other genes … Continued
A new study found that patients who received heated intraperitoneal chemotherapy (HIPEC) after surgery lived almost 16 months longer than patients who were treated by surgery alone. Conducted with data from 584 patients with stage III epithelial ovarian cancer from multiple treatment centers, this study is the largest to date looking at the effects of … Continued
Ovarian Cancer Research Alliance (OCRA) is thrilled to announce a groundbreaking partnership with Microsoft’s AI for Health initiative. This unique collaboration will help OCRA accelerate ovarian cancer research by harnessing the power of data science and Artificial Intelligence (AI). With the support of Microsoft’s AI for Health initiative, a $60 million, five-year program, select OCRA grantees can utilize Microsoft’s … Continued
(August 6, 2020) Using medical records for 121 patients with gynecologic cancer and COVID-19, researchers were able to conduct an early look at the implications of a COVID-19 diagnosis on a patient with a gynecological cancer diagnosis. All of these patients were treated in the New York City area. Seventeen of the 121 patients (14.0%) … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
